Simvastatin Suppresses Proliferation and Migration in Non-small Cell Lung Cancer via Pyroptosis

Pyroptosis is a form of caspase-1-dependent programmed cell death with anti-tumor properties, but the underlying molecular mechanisms are not fully understood. The results of our study showed that the antihyperlipidemic drug simvastatin induced pyroptosis in non-small cell lung cancer (NSCLC) cell l...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Fengjiao, Liu, Wei, Ning, Jinfeng, Wang, Junfeng, Lang, Yaoguo, Jin, Xiangyuan, Zhu, Kaibin, Wang, Xiuyun, Li, Xiaoguang, Yang, Fan, Ma, Jianqun, Xu, Shidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5930473/
https://www.ncbi.nlm.nih.gov/pubmed/29725262
http://dx.doi.org/10.7150/ijbs.23542
Descripción
Sumario:Pyroptosis is a form of caspase-1-dependent programmed cell death with anti-tumor properties, but the underlying molecular mechanisms are not fully understood. The results of our study showed that the antihyperlipidemic drug simvastatin induced pyroptosis in non-small cell lung cancer (NSCLC) cell lines and a xenograft mouse model. Inhibition of pyroptosis attenuated the effects of simvastatin on tumor cell viability and migration. These data suggest that simvastatin may induce pyroptosis, thereby potentially serving as a novel therapeutic agent for NSCLC.

Ejemplares similares